Insulet Corp. Hits New 52-Week Low at $216.51 Amid Market Challenges

Insulet Corp., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 216.51 on March 13, 2026. This decline marks a significant point in the stock's performance, particularly as it contrasts with the stock's 52-week high of USD 354.88. Over the past year, Insulet has recorded a performance of 14.48%, which falls short of the S&P 500's 20.12% return. The company's market capitalization stands at USD 17,028 million, with a price-to-earnings ratio of 68.00. Despite a healthy long-term growth trajectory, evidenced by a net sales growth rate of 24.53% and an operating profit increase of 55.87%, Insulet has faced challenges in profitability, reflected in a low return on capital employed (ROCE) of 11.86%. Additionally, the stock has seen a decline in profits by 14.9% over the past year, contributing to its below-par performance relative to the broader market. With a debt-equity ratio of 0.16 and a return on equity of 22.52%, Insulet's financial metrics indicate a complex landscape as it navigates current market conditions.